GLIORESOLVE: TRAINING THE NEXT-GENERATION OF EUROPEAN GLIOBLASTOMA (TRANSLATIONAL) RESEARCHERS, TO RESOLVE PRECISION TARGETING OF THE BRAIN TUMOUR MICROENVIRONMENT
Glioblastoma (GBM) is the most frequent, aggressive and lethal brain tumour. It has a universally fatal prognosis with 85% of patients dying within two years. Despite significant efforts clinicians are as yet unable to offer GBM patients a curative therapy. Effective precision medicine therapies are thus urgently required. The GBM tumour microenvironment (TME) consists of various cell types including the cancer cells themselves, but also non-cancerous cells such as normal brain cells (glial cells and microglia), vascular cells and different types of immune cells. The interactions between all of these cells is known to contribute to the intractability of this disease. Overall, the project seeks to identify a new TME-targeting platform for GBM brain tumours.
The GLIORESOLVE project will exploit this urgent clinical need for novel precision medicine strategies to train a new generation of highly skilled doctoral candidates (PhD candidates) in the neuro-oncology, immune-oncology and digital pathology/spatial ‘omics’ domain.
The consortium comprises 21 international organisations and brings together leading academics, clinicians, private sector and not-for-profit partners from 10 countries. It incorporates disruptive research methods including multi-omics, ex-vivo ‘tumour-on-a-chip’ assay development, computational modelling and systems biology.
More information can be found here: GLIORESOLVE
LPCM’s project in this consortium is: Mapping the therapeutic potential of AG5 and its effects om TME using a multiomics approach in IDHwt GBM patient-derived models.
Recently, Ag5 was identified as a potential cancer therapy. Ag5 damages mitochondrial function via elevated levels of reactive oxygen species (ROS). Considering that GBM and GSCs are characterized by high ROS levels and that Ag5 can easily cross the BBB, Ag5 harbours therapeutic potential in GBM